Jianhua Luo
University of Pittsburgh School of Medicine, USA
Title: Genome biomarkers of prostate cancer
Biography
Biography: Jianhua Luo
Abstract
Accurate prediction of prostate cancer clinical courses remains elusive. In recent studies, we performed whole genome analysis on prostate cancers by combining Affymetrix SNP6.0 chip, whole genome sequencing and transcriptome sequencing. Our results showed that combination of genome copy number variance and novel fusion transcripts specific for cancer achieved high accuracy in predicting prostate cancer outcomes. The prediction model was further improved when these molecular criteria were combined with Nomogram or Gleason’s grading, leukocyte CNV. Interestingly, some of these fusion genes are also present in a variety of human malignancies. Some of these fusion genes play critical roles in developing malignancies. Critical signaling pathways associated with some of these fusion genes have been characterized. Targeting at fusion gene appears to be an effective approach in killing cancer cells both in vitro and in vivo, and holds promise as a new treatment for human malignancies.
